Cipher Pharmaceuticals Inc. (T:CPH*CA)

Business Focus: Pharmaceuticals (NEC)

Sector:  Healthcare Industry:  Pharmaceuticals
 
Company Contact
Address: 5750 Explorer Drive,, Suite 404
MISSISSAUGA ON L4W 0A9
Tel: N/A
Website: https://www.cipherpharma.com
IR: See website
<
Key People
Craig J. Mull
Chairman of the Board, Interim Chief Executive Officer
Bryan Jacobs
Chief Financial Officer
Diane Gajewczyk
Vice President - Scientific and Medical Affairs
Business Overview
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.
Financial Overview
For the fiscal year ended 31 December 2023, Cipher Pharmaceuticals Inc revenues increased 2% to $21.2M. Net income decreased 23% to $20.4M. Revenues reflect Licensing revenue increase of 4% to $8.5M, Product revenue increase of 1% to $12.7M. Net income was offset by Research and development increase of 42% to $139K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from $1.05 to $0.82.
Employees: 6 as of Dec 31, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $151.33M as of Dec 31, 2023
Annual revenue (TTM): $28.91M as of Dec 31, 2023
EBITDA (TTM): $15.38M as of Dec 31, 2023
Net annual income (TTM): $27.84M as of Dec 31, 2023
Free cash flow (TTM): $21.66M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 24,107,316 as of Apr 12, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.